Cargando…

Mechanism of Action and Clinical Attributes of Auryxia(®) (Ferric Citrate)

Chronic kidney disease (CKD) is a major cause of morbidity and premature mortality and represents a significant global public health issue. Underlying this burden are the many complications of CKD, including mineral and bone disorders, anemia, and accelerated cardiovascular disease. Hyperphosphatemi...

Descripción completa

Detalles Bibliográficos
Autores principales: Ganz, Tomas, Bino, Avi, Salusky, Isidro B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6562046/
https://www.ncbi.nlm.nih.gov/pubmed/31134521
http://dx.doi.org/10.1007/s40265-019-01125-w
_version_ 1783426223569895424
author Ganz, Tomas
Bino, Avi
Salusky, Isidro B.
author_facet Ganz, Tomas
Bino, Avi
Salusky, Isidro B.
author_sort Ganz, Tomas
collection PubMed
description Chronic kidney disease (CKD) is a major cause of morbidity and premature mortality and represents a significant global public health issue. Underlying this burden are the many complications of CKD, including mineral and bone disorders, anemia, and accelerated cardiovascular disease. Hyperphosphatemia and elevated levels of fibroblast growth factor 23 (FGF23) have been identified as key independent risk factors for the adverse cardiovascular outcomes that frequently occur in patients with CKD. Auryxia(®) (ferric citrate; Keryx Biopharmaceuticals, Inc., Boston, MA, USA) is an iron-based compound with distinctive chemical characteristics and a mechanism of action that render it dually effective as a therapy in patients with CKD; it has been approved as a phosphate binder for the control of serum phosphate levels in adult CKD patients treated with dialysis and as an iron replacement product for the treatment of iron deficiency anemia in adult CKD patients not treated with dialysis. This review focuses on Auryxia, its mechanism of action, and the clinical attributes that differentiate it from other, non-pharmaceutical-grade, commercially available forms of ferric citrate and from other commonly used phosphate binder and iron supplement therapies for patients with CKD. Consistent with the chemistry and mechanism of action of Auryxia, multiple clinical studies have demonstrated its efficacy in both lowering serum phosphate levels and improving iron parameters in patients with CKD. Levels of FGF23 decrease significantly with Auryxia treatment, but the effects associated with the cardiovascular system remain to be evaluated in longer-term studies.
format Online
Article
Text
id pubmed-6562046
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-65620462019-06-28 Mechanism of Action and Clinical Attributes of Auryxia(®) (Ferric Citrate) Ganz, Tomas Bino, Avi Salusky, Isidro B. Drugs Review Article Chronic kidney disease (CKD) is a major cause of morbidity and premature mortality and represents a significant global public health issue. Underlying this burden are the many complications of CKD, including mineral and bone disorders, anemia, and accelerated cardiovascular disease. Hyperphosphatemia and elevated levels of fibroblast growth factor 23 (FGF23) have been identified as key independent risk factors for the adverse cardiovascular outcomes that frequently occur in patients with CKD. Auryxia(®) (ferric citrate; Keryx Biopharmaceuticals, Inc., Boston, MA, USA) is an iron-based compound with distinctive chemical characteristics and a mechanism of action that render it dually effective as a therapy in patients with CKD; it has been approved as a phosphate binder for the control of serum phosphate levels in adult CKD patients treated with dialysis and as an iron replacement product for the treatment of iron deficiency anemia in adult CKD patients not treated with dialysis. This review focuses on Auryxia, its mechanism of action, and the clinical attributes that differentiate it from other, non-pharmaceutical-grade, commercially available forms of ferric citrate and from other commonly used phosphate binder and iron supplement therapies for patients with CKD. Consistent with the chemistry and mechanism of action of Auryxia, multiple clinical studies have demonstrated its efficacy in both lowering serum phosphate levels and improving iron parameters in patients with CKD. Levels of FGF23 decrease significantly with Auryxia treatment, but the effects associated with the cardiovascular system remain to be evaluated in longer-term studies. Springer International Publishing 2019-05-27 2019 /pmc/articles/PMC6562046/ /pubmed/31134521 http://dx.doi.org/10.1007/s40265-019-01125-w Text en © The Author(s) 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Review Article
Ganz, Tomas
Bino, Avi
Salusky, Isidro B.
Mechanism of Action and Clinical Attributes of Auryxia(®) (Ferric Citrate)
title Mechanism of Action and Clinical Attributes of Auryxia(®) (Ferric Citrate)
title_full Mechanism of Action and Clinical Attributes of Auryxia(®) (Ferric Citrate)
title_fullStr Mechanism of Action and Clinical Attributes of Auryxia(®) (Ferric Citrate)
title_full_unstemmed Mechanism of Action and Clinical Attributes of Auryxia(®) (Ferric Citrate)
title_short Mechanism of Action and Clinical Attributes of Auryxia(®) (Ferric Citrate)
title_sort mechanism of action and clinical attributes of auryxia(®) (ferric citrate)
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6562046/
https://www.ncbi.nlm.nih.gov/pubmed/31134521
http://dx.doi.org/10.1007/s40265-019-01125-w
work_keys_str_mv AT ganztomas mechanismofactionandclinicalattributesofauryxiaferriccitrate
AT binoavi mechanismofactionandclinicalattributesofauryxiaferriccitrate
AT saluskyisidrob mechanismofactionandclinicalattributesofauryxiaferriccitrate